Child-onset and adolescent-onset acquired thrombotic thrombocytopenic purpura with severe ADAMTS13 deficiency: a cohort study of the French national registry for thrombotic microangiopathy

The Lancet Haematology

Volumn 3, Issue 11, 2016, Pages e537-e546

  Joly, Bérangère S ^a   Stepanian, Alain ^a   Leblanc, Thierry ^b   Hajage, David ^c   Chambost, Hervé ^d   Harambat, Jérôme ^e   Fouyssac, Fanny ^f   Guigonis, Vincent ^g   Leverger, Guy ^h   Ulinski, Tim ^h   Kwon, Thérésa ^b   Loirat, Chantal ^b   Coppo, Paul ⁱ   Veyradier, Agnès ^a  

^a HÔPITAL LARIBOISIÈRE   (France)

^b HÔPITAL ROBERT DEBRÉ   (France)

^c HÔPITAL LOUIS MOURIER   (France)

^d TIMONE HOSPITAL   (France)

^e HÔPITAL PELLEGRIN   (France)

^f HÔPITAL D ENFANTS   (France)

^g LIMOGES UNIVERSITY HOSPITAL   (France)

^h ARMAND TROUSSEAU HOSPITAL   (France)

ⁱ ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYCHLOROQUINE; RITUXIMAB; STEROID; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; ADAMTS13 PROTEIN, HUMAN; AUTOANTIBODY; IMMUNOSUPPRESSIVE AGENT;

ADOLESCENT; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL OUTCOME; CLINICAL TRIAL; COMORBIDITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; MULTIPLE CYCLE TREATMENT; PLASMA EXCHANGE; PRIORITY JOURNAL; PROTEIN DEFICIENCY; RECURRENCE RISK; SPLENECTOMY; THROMBOTIC THROMBOCYTOPENIC PURPURA; AGE; ANTAGONISTS AND INHIBITORS; AUTOIMMUNE DISEASE; BLOOD; BLOOD COMPONENT THERAPY; COHORT ANALYSIS; COMPLICATION; CROSS-SECTIONAL STUDY; DEFICIENCY; DIAGNOSTIC ERROR; DIFFERENTIAL DIAGNOSIS; DISEASE EXACERBATION; DISEASE FREE SURVIVAL; EPSTEIN BARR VIRUS INFECTION; ESCHERICHIA COLI INFECTION; FRANCE; GENETIC PREDISPOSITION; GROWTH DISORDER; HEMOLYTIC UREMIC SYNDROME; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INFANT; KIDNEY DISEASE; KIDNEY FAILURE; LIVER FAILURE; OBESITY; PNEUMOCOCCAL INFECTION; PRESCHOOL CHILD; PROCEDURES; PROGNOSIS; PROSPECTIVE STUDY; PSYCHOMOTOR DISORDER; PSYCHOTHERAPY; RARE DISEASE; RECURRENT DISEASE; REGISTER; RISK FACTOR; ROTAVIRUS INFECTION; SECONDARY PREVENTION; SEX DIFFERENCE; STATISTICS AND NUMERICAL DATA; SURVIVAL RATE; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME;

ADAMTS13 PROTEIN; ADOLESCENT; AGE FACTORS; AUTOANTIBODIES; AUTOIMMUNE DISEASES; BLOOD COMPONENT TRANSFUSION; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; COMORBIDITY; CROSS-SECTIONAL STUDIES; DIAGNOSIS, DIFFERENTIAL; DIAGNOSTIC ERRORS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; EPSTEIN-BARR VIRUS INFECTIONS; ESCHERICHIA COLI INFECTIONS; FEMALE; FOLLOW-UP STUDIES; FRANCE; GENETIC PREDISPOSITION TO DISEASE; GROWTH DISORDERS; HEMOLYTIC-UREMIC SYNDROME; HEPATIC INSUFFICIENCY; HUMANS; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENTS; INFANT; KIDNEY DISEASES; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; OVERWEIGHT; PLASMA EXCHANGE; PNEUMOCOCCAL INFECTIONS; PROGNOSIS; PROSPECTIVE STUDIES; PSYCHOMOTOR DISORDERS; PSYCHOTHERAPY; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; PURPURA, THROMBOTIC THROMBOCYTOPENIC; RARE DISEASES; RECURRENCE; REGISTRIES; RENAL INSUFFICIENCY; RISK FACTORS; RITUXIMAB; ROTAVIRUS INFECTIONS; SECONDARY PREVENTION; SEX FACTORS; SPLENECTOMY; STEROIDS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84992754323     PISSN: None     EISSN: 23523026     Source Type: Journal    
DOI: 10.1016/S2352-3026(16)30125-9     Document Type: Article

References (33)

1. 1 George, JN, Nester, CM, Syndromes of thrombotic microangiopathy. N Engl J Med 371 (2014), 654–666.
2. 2 Bouw, MC, Dors, N, van Ommen, H, et al. Thrombotic thrombocytopenic purpura in childhood. Pediatr Blood Cancer 53 (2009), 537–542.
3. 3 Pisoni, R, Remuzzi, G, Thrombotic microangiopathy. Eur J Intern Med 11 (2000), 135–139.
4. 4 Moschcowitz, E, Hyaline thrombosis of the terminal arterioles and capillaries: a hitherto undescribed disease. Proc N Pathol Soc 24 (1924), 21–24.
5. 5 Furlan, M, Robles, R, Galbusera, M, et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 339 (1998), 1578–1584.
6. 6 Tsai, HM, Lian, EC, Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 339 (1998), 1585–1594.
7. 7 Levy, GG, Nichols, WC, Lian, EC, et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 413 (2001), 488–494.
8. 8 von Krogh, AS, Quist-Paulsen, P, Waage, A, et al. High prevalence of hereditary thrombotic thrombocytopenic purpura in central Norway: from clinical observation to evidence. J Thromb Haemost 14 (2016), 73–82.
9. 9 Matsumoto, M, Kokame, K, Soejima, K, et al. Molecular characterization of ADAMTS13 gene mutations in Japanese patients with Upshaw-Schulman syndrome. Blood 103 (2004), 1305–1310.
10. 10 Veyradier, A, Lavergne, J-M, Ribba, A-S, et al. Ten candidate ADAMTS13 mutations in six French families with congenital thrombotic thrombocytopenic purpura (Upshaw-Schulman syndrome). J Thromb Haemost 2 (2004), 424–429.
11. 11 Hommais, A, Rayes, J, Houllier, A, et al. Molecular characterization of four ADAMTS13 mutations responsible for congenital thrombotic thrombocytopenic purpura (Upshaw-Schulman syndrome). Thromb Haemost 98 (2007), 593–599.
12. 12 Sadler, JE, What's new in the diagnosis and pathophysiology of thrombotic thrombocytopenic purpura. Am Soc Hematol Educ Program 2015 (2015), 631–636.
13. 13 Tsai, H-M, Raoufi, M, Zhou, W, et al. ADAMTS13-binding IgG are present in patients with thrombotic thrombocytopenic purpura. Thromb Haemost 95 (2006), 886–892.
14. 14 Ferrari, S, Mudde, GC, Rieger, M, et al. IgG subclass distribution of anti-ADAMTS13 antibodies in patients with acquired thrombotic thrombocytopenic purpura. J Thromb Haemost 7 (2009), 1703–1710.
15. 15 Schaller, M, Vogel, M, Kentouche, K, et al. The splenic autoimmune response to ADAMTS13 in thrombotic thrombocytopenic purpura contains recurrent antigen-binding CDR3 motifs. Blood 124 (2014), 3469–3479.
16. 16 Isonishi, A, Bennett, CL, Plaimauer, B, et al. Poor responder to plasma exchange therapy in acquired thrombotic thrombocytopenic purpura is associated with ADAMTS13 inhibitor boosting: visualization of an ADAMTS13 inhibitor complex and its proteolytic clearance from plasma. Transfusion 55 (2015), 2321–2330.
17. 17 Hie, M, Gay, J, Galicier, L, et al. Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura. Blood 124 (2014), 204–210.
18. 18 Cines, DB, Blanchette, VS, Immune thrombocytopenic purpura. N Engl J Med 346 (2002), 995–1008.
19. 19 Miano, M, How I manage Evans Syndrome and AIHA cases in children. Br J Haematol 172 (2016), 524–534.
20. 20 Mansouri Taleghani, M, von Krogh, A-S, Fujimura, Y, et al. Hereditary thrombotic thrombocytopenic purpura and the hereditary TTP registry. Hämostaseologie 33 (2013), 138–143.
21. 21 Reese, JA, Muthurajah, DS, Kremer Hovinga, JA, et al. Children and adults with thrombotic thrombocytopenic purpura associated with severe, acquired Adamts13 deficiency: comparison of incidence, demographic and clinical features. Pediatr Blood Cancer 60 (2013), 1676–1682.
22. 22 Jayabose, S, Nowicki, TS, Dunbar, J, et al. Acquired thrombotic thrombocytopenic purpura in children: a single institution experience. Indian J Pediatr 80 (2013), 570–575.
23. 23 Sankararaman, S, Jeroudi, M, Ibrahim, H, Successful treatment of relapsing autoimmune thrombotic thrombocytopenic purpura with rituximab. Pediatr Int Off 56 (2014), 914–918.
24. 24 Wieland, I, Kentouche, K, Jentzsch, M, et al. Long-term remission of recurrent thrombotic thrombocytopenic purpura (TTP) after Rituximab in children and young adults. Pediatr Blood Cancer 62 (2015), 823–829.
25. 25 Veyradier, A, Obert, B, Houllier, A, et al. Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases. Blood 98 (2001), 1765–1772.
26. 26 Obert, B, Tout, H, Veyradier, A, et al. Estimation of the von Willebrand factor-cleaving protease in plasma using monoclonal antibodies to vWF. Thromb Haemost 82 (1999), 1382–1385.
27. 27 Gerritsen, HE, Turecek, PL, Schwarz, HP, et al. Assay of von Willebrand factor (vWF)-cleaving protease based on decreased collagen binding affinity of degraded vWF: a tool for the diagnosis of thrombotic thrombocytopenic purpura (TTP). Thromb Haemost 82 (1999), 1386–1389.
28. 28 Kokame, K, Nobe, Y, Kokubo, Y, et al. FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol 129 (2005), 93–100.
29. 29 Moatti-Cohen, M, Garrec, C, Wolf, M, et al. Unexpected frequency of Upshaw-Schulman syndrome in pregnancy-onset thrombotic thrombocytopenic purpura. Blood 119 (2012), 5888–5897.
30. 30 Noris, M, Remuzzi, G, Atypical hemolytic-uremic syndrome. N Engl J Med 36 (2009), 1676–1887.
31. 31 Mariotte, E, Azoulay, E, Galicier, L, et al. Epidemiology and pathophysiology of adulthood-onset thrombotic microangiopathy with severe ADAMTS13 deficiency (thrombotic thrombocytopenic purpura): a cross-sectional analysis of the French national registry for thrombotic microangiopathy. Lancet Haematol 3 (2016), e237–e245.
32. 32 Han, B, Page, EE, Stewart, LM, et al. Depression and cognitive impairment following recovery from thrombotic thrombocytopenic purpura. Am J Hematol 90 (2015), 709–714.
33. 33 Coppo, P, Froissart, A, Treatment of thrombotic thrombocytopenic purpura beyond therapeutic plasma exchange. Am Soc Hematol Educ Program 2015 (2015), 637–643.